This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Isoniazid in Pulmonary Tuberculosis.
—The second report of the Medical Research Council's Tuberculosis Chemotherapy Trials Committee on isoniazid in the treatment of pulmonary tuberculosis (Brit. M. J. 1:521, 1953) is based on the findings in 364 patients after three months' treatment. Three forms of treatment were used: 142 patients were treated with streptomycin (1 gm. daily) and isoniazid (100 mg. twice daily); 102 with streptomycin (1 gm. daily) and p-aminosalicylic acid (5 gm. four times daily); and 120 with isoniazid (100 mg. twice daily) alone. The criteria for acceptance of a patient for inclusion in the trial were as follows: 1. Tubercle bacilli had to be demonstrated. 2. The tubercle bacilli could not be streptomycin-resistant or p-aminosalicylic acid-resistant. 3. The patient could not have had more than 15 gm. of streptomycin and/or 300 gm. of p-aminosalicylic acid within the previous three months, and not more than
LONDON. JAMA. 1953;152(6):548. doi:10.1001/jama.1953.03690060064024